Regencell Bioscience Holdings shares fall 1.90% intraday after releasing new drug candidates and increased investor interest in financial reports.

Regencell Bioscience Holdings Limited fell 1.90% intraday, as the company announced the launch of three liquid-based standardized traditional Chinese medicine formulations for treating mild, moderate, and severe ADHD and ASD patients by July 10, 2025. Additionally, investors are closely monitoring the company's financial report, with call options trading volume exceeding put options by three times and an implied volatility of 12.2%, indicating market expectations of short-term price fluctuations.